Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4

Detalles Bibliográficos
Autores principales: Ishida, Yuriko, Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835993/
https://www.ncbi.nlm.nih.gov/pubmed/36655228
http://dx.doi.org/10.1183/23120541.00337-2022
Descripción
Sumario:This article is a correspondence to the review article on lung cancer with comorbid interstitial pneumonia, particularly with regard to pharmacotherapy. Limited evidence needs to be accurately evaluated and utilised for these patients with poor prognosis. https://bit.ly/3BGRCz4

Ejemplares similares